Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of ABT-450/r/ombitasvir plus dasabuvir and ribavirin in liver transplant recipients with genotype 1 hepatitis C
2012-004792-39Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paritaprevir, ritonavir, ombitasvir, dasabuvir, ribavirin in hepatitis C virus infection, Hepatitis C genotype 1, sponsored by AbbVie Inc.. Started Mar 2013; status: completed.
02
Drugs
paritaprevirritonavirombitasvirdasabuvirribavirin
03
Conditions
hepatitis C virus infectionHepatitis C genotype 1
Beyond the preview
Go deeper on 2012-004792-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004792-39.